These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36267268)

  • 41. Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.
    Al-Samkari H
    Drugs Today (Barc); 2018 Nov; 54(11):647-655. PubMed ID: 30539164
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.
    Bussel JB; Kuter DJ; Aledort LM; Kessler CM; Cuker A; Pendergrass KB; Tang S; McIntosh J
    Blood; 2014 Jun; 123(25):3887-94. PubMed ID: 24802775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Flisiak R; Antonov K; Drastich P; Jarcuska P; Maevskaya M; Makara M; Puljiz Ž; Štabuc B; Trifan A
    J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo.
    Scheding S; Bergmann M; Shimosaka A; Wolff P; Driessen C; Rathke G; Jaschonek K; Brugger W; Kanz L
    Transfusion; 2002 Mar; 42(3):321-7. PubMed ID: 11961237
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
    Zhang X; Chuai Y; Nie W; Wang A; Dai G
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis.
    Temel T; Cansu DU; Temel HE; Ozakyol AH
    Hepat Mon; 2014 May; 14(5):e18556. PubMed ID: 24976834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia.
    Al-Samkari H; Kuter DJ
    Ther Adv Hematol; 2019; 10():2040620719841735. PubMed ID: 31007886
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thrombocytopenia in Chronic Liver Disease and the Role of Thrombopoietin Agonists.
    Miller JB; Figueroa EJ; Haug RM; Shah NL
    Gastroenterol Hepatol (N Y); 2019 Jun; 15(6):326-332. PubMed ID: 31391802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and Safety of Avatrombopag in Patients with Chronic Immune Thrombocytopenia: A Systematic Literature Review and Network Meta-Analysis.
    Wojciechowski P; Wilson K; Nazir J; Pustułka I; Tytuła A; Smela B; Pochopien M; Vredenburg M; McCrae KR; Jurczak W
    Adv Ther; 2021 Jun; 38(6):3113-3128. PubMed ID: 33934279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice.
    Chang M; Qian JX; Lee SM; Joubran J; Fernandez G; Nichols J; Knoppel A; Buzby JS
    Blood; 1999 Apr; 93(8):2515-24. PubMed ID: 10194430
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
    Desborough M; Hadjinicolaou AV; Chaimani A; Trivella M; Vyas P; Doree C; Hopewell S; Stanworth SJ; Estcourt LJ
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012055. PubMed ID: 27797129
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review.
    Birocchi S; Podda GM; Manzoni M; Casazza G; Cattaneo M
    Platelets; 2021 Feb; 32(2):216-226. PubMed ID: 32281449
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The burden associated with thrombocytopenia and platelet transfusions among patients with chronic liver disease.
    Elsaid MI; Rustgi VK; Loo N; Aggarwal K; Li-McLeod J; Niu X; Poordad F
    J Med Econ; 2020 Apr; 23(4):378-385. PubMed ID: 31777291
    [No Abstract]   [Full Text] [Related]  

  • 54. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blunted thrombopoietin response to interferon alfa-induced thrombocytopenia during treatment for hepatitis C.
    Peck-Radosavljevic M; Wichlas M; Pidlich J; Sims P; Meng G; Zacherl J; Garg S; Datz C; Gangl A; Ferenci P
    Hepatology; 1998 Nov; 28(5):1424-9. PubMed ID: 9794931
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.
    Gallo P; Terracciani F; Di Pasquale G; Esposito M; Picardi A; Vespasiani-Gentilucci U
    World J Gastroenterol; 2022 Aug; 28(30):4061-4074. PubMed ID: 36157107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Thrombopoietin Receptor Agonist Lusutrombopag Is Effective for Patients with Chronic Liver Disease and Impaired Renal Function.
    Takeuchi H; Furuichi Y; Yoshimasu Y; Kasai Y; Abe M; Sugimoto K; Itoi T
    J Nippon Med Sch; 2021 Jan; 87(6):325-333. PubMed ID: 32238734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.